



Pharma Finance 2007

ROMA - ITALY - MAY 10-11

5TH ANNUAL PARTNERING CONFERENCE

Market Data (AS OF MAY 1, 2007)



Symbol	MHA
Exchange	AMEX
Current Price	\$1.03
Shares Outstanding	60.12M
Market Capital	\$62.34M
52wk RANGE	\$0.60-\$1.41
Average Volume	91,706
YTD % Change	-16.67%

COMPANY FACT SHEET



Manhattan Pharmaceuticals, Inc.
 810 7th Avenue, 4th Floor
 New York, NY 10019
 (212) 582-3950

www.manhattanpharma.com



Douglas Abel
 Chief Executive Officer

FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

Net Revenue:	N/A	Earnings per Share:	(0.16)
Net Income:	(9.70M)	Weighted Average:	60.1M

CONFERENCE OBJECTIVES

Partnering and Licensing opportunities.

RECENT DEVELOPMENTS

April 4, 2007

Manhattan Pharmaceuticals Announces License Agreement and Expanded Pipeline

April 2, 2007

Manhattan Pharmaceuticals Completes \$8.6 Million Private Placement

February 21, 2007

Manhattan Pharmaceuticals Completes Enrollment in Phase 2a Study of Oral Oleoyl-estrone for Obesity

PRODUCT AND PRODUCT CANDIDATE PIPELINE

Product	Indication	Status
Topical PTH1-34	Psoriasis	Phase 1/2
Altoderm™ (topical cromolyn sodium)	Atopic dermatitis	Pre-IND (US) Phase 3 (UK)
Oral Oleoyl-estrone	Obesity	Phase 2a
Oral Oleoyl-estrone	Morbid obesity	Phase 2a
Altolyn™ (oral cromolyn sodium tablet)	Mastocytosis	Pre-IND (US) Early clinical (UK)
Propofol Lingual Spray	Pre-procedural sedation	Phase 1

Company Description

Manhattan Pharmaceuticals, Inc. is a development-stage pharmaceutical company that acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing Oral Oleoyl-estrone, a novel therapeutic for the treatment of both common obesity and morbid obesity. To meet the needs of other, large, but underserved, dermatological markets Manhattan Pharmaceuticals is developing topical PTH1-34 for the treatment of psoriasis, and Altoderm™ (topical cromolyn sodium) for the treatment of atopic dermatitis. The company is also developing Altolyn™ (oral cromolyn sodium tablet) for the treatment of mastocytosis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol as a sedative-hypnotic for use during diagnostic and therapeutic procedures.